CNS pipeline · person
Robert Berman, MD
Member of the Board of Directors of Gilgamesh Pharmaceuticals. Co-founder of Biohaven Pharmaceuticals, adjunct professor at Yale University, and lead author of the seminal study of ketamine in depressed patients (Berman et al., 2000).
- 2 companies
Current roles
- Gilgamesh Pharmaceuticals, Inc.Member, Board of Directors · Board
- Syndeio Biosciences, Inc.Senior Clinical Advisor · Advisor
Appears with
People sharing a company with Robert.
- Amy Kruse · Gilgamesh Pharmaceuticals, Inc.
- Anantha Shekhar · Syndeio Biosciences, Inc.
- Daniel Umbricht · Gilgamesh Pharmaceuticals, Inc.
- Derek Small · Syndeio Biosciences, Inc.
- Ed Christian · Gilgamesh Pharmaceuticals, Inc.
- Gerard Marek · Gilgamesh Pharmaceuticals, Inc.
- Jacob Vogelstein · Syndeio Biosciences, Inc.
- John Donello · Syndeio Biosciences, Inc.
- Jonathan Sporn · Gilgamesh Pharmaceuticals, Inc.
- Joseph R. Moskal · Syndeio Biosciences, Inc.
- Laszlo Kiss · Gilgamesh Pharmaceuticals, Inc.
- Mark DiPaolo · Syndeio Biosciences, Inc.
- Michael G. McCully · Syndeio Biosciences, Inc.
- Pavel Raifeld · Syndeio Biosciences, Inc.
- Phil Skolnick · Gilgamesh Pharmaceuticals, Inc.
- Steve Brannan · Syndeio Biosciences, Inc.
- Thomas C. Sudhof · Syndeio Biosciences, Inc.
- Yoni Falkson · Gilgamesh Pharmaceuticals, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.